The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Imp
- PDF / 1,329,149 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 9 Downloads / 141 Views
ORIGINAL RESEARCH ARTICLE
The Role of Delafloxacin in Patients with Community‑Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model Thomas P. Lodise1 · Glenn S. Tillotson2 · Andrew Spargo3 · Duygu Bozkaya3 · Jill Massey4,5
© The Author(s) 2020
Abstract Background and Objective Community-acquired bacterial pneumonia (CABP) affects millions of people each year in the USA. The majority of patients with CABP are treated in the community setting with empirical antimicrobial therapy. Delafloxacin is an anionic fluoroquinolone approved for the treatment of adult patients with CABP. This de novo analysis sought to estimate the budget impact of delafloxacin in the treatment of adult patients with CABP in the outpatient setting from the payer’s perspective. Methods A budget impact model (BIM) was developed from the perspective of a US third-party payer to estimate the cost of introducing delafloxacin for the outpatient treatment of CABP over a 1-year time horizon. Population, clinical, and cost inputs were based on the available literature, clinical trial data, and real-world evidence studies. Scenario analyses were conducted to evaluate the potential budget impact among COPD/asthma patients based on the findings from the phase III trial of delafloxacin for CABP, which indicated that patients with COPD or asthma may experience improved effectiveness with delafloxacin compared to moxifloxacin. Results In the base-case analysis, with a hypothetical plan of 1,000,000 members, the model estimated that adding delafloxacin to the formulary resulted in a total budget impact of $58,987. This increase was mainly attributed to treatment acquisition costs. In the scenario analysis that was restricted to COPD/asthma patients, adding delafloxacin to the formulary was estimated to result in a total budget impact of $5,042. Conclusion The results of the budget impact analyses provide conservative estimates of the impact of adding delafloxacin to outpatient formularies in substitution of moxifloxacin.
Key Points
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40261-020-00938-y) contains supplementary material, which is available to authorized users. * Jill Massey [email protected] 1
Albany College of Pharmacy and Health Sciences, Albany, NY, USA
2
GST Micro LLC, Henrico, VA, USA
3
Xcenda, Tampa, FL, USA
4
Melinta Therapeutics, Inc., Morristown, NJ, USA
5
Present Address: Immunomedics, Inc., Morris Plains, NJ, USA
Total budget impact was primarily driven by an increase in pharmacy costs, with treatment acquisition cost being the main driver of cost increase. Generic antibiotics comprised the largest market share in the comparator model, the costs of which are largely covered by insurance co-pays. Compared to the current environment without delafloxacin, a decrease in medical costs was seen in the new environment with delafloxacin. The scenario analysis suggests use of delafloxacin in patients with COPD/asthma may minimize its overal
Data Loading...
